EGeen and Prediction Sciences sign a deal to study pharmacogenetics of hypertension treatment
Redwood City, CA, and San Diego, CA. - February 28, 2003 EGeen International and Prediction Sciences announced today the signing of an agreement to collaborate on the discovery of genetic variants responsible for variable patient response to major classes of hypertension drugs. Financial details of the agreement were not disclosed. "EGeen is building a major pharmacogenetic capability uniquely empowered by its network of medical professionals and the ethical-legal structure set up in Estonia to ensure data confidentiality. We are extremely pleased with the expansion of the collaboration with Prediction Sciences into hypertension, a major therapeutic area", said Kalev Kask, co-founder and CEO of EGeen. Prediction Sciences will use its proprietary bioinformatic algorithms to associate patient chart information and SNP profiles with outcome of treatment. The developed product is intended for the use in the clinic as a predictive indicator of a patient's likelihood to respond to hypertension treatment. "With the advanced bioinformatic capabilities and disease-specific expertise of Prediction Sciences applied to the extensive clinical database of EGeen, we believe this agreement marks the continuation of a productive and profitable relationship", said Albert Man, Ph.D., Director of Business Development at Prediction Sciences. About EGeen International Corporation EGeen International is a privately held emerging biotechnology company focused on drug and diagnostic target discovery, and personalized medicine applications. EGeen has exclusive commercial rights to information from the Estonian Gene Bank. The Estonian Gene Bank project is a major national effort sponsored by the Estonian Government with the objective of gathering medical information and samples from a significant portion of the population. The Company will continue to establish biopharmaceutical and pharmacogenetic collaborations with partners seeking to validate drug target candidates and genetic drug profiles. More information about the Company can be found at http://www.EGeeninc.com About Prediction Sciences Prediction Sciences is a privately owned pharmacogenomics company based in San Diego, CA, focused on developing molecular diagnostics for patient stratification and treatment outcome in oncology, cardiology, and CNS disorders. The company is applying its GeneRxTM technology toward clinical trials optimization and the rescue of low efficacy drugs to more targeted patient populations. More information about the Company can be found at http://www.predict.net. EGeen International Corporation Prediction Sciences, LLC |